Abstract
Background: ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp). In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics. Phase I trials of ONT-093 in normal human volunteers showed no dose-limiting toxicities at serum concentrations associated with biologic activity achieved with doses ranging from 300 to 500 mg. Methods: Phase I pharmacokinetic trial of ONT-093 in doses from 300 to 500 mg administered before and after intravenous paclitaxel doses of 150 to 175 mg/m2 repeated every 21 days. All patients received paclitaxel alone on cycle 1. Results: 18 patients were enrolled onto 4 dose levels. Toxicity of the combination included neutropenia, arthralgia, myalgia, and peripheral neuropathy. Four of 6 patients receiving 500 mg doses of ONT-093 and paclitaxel at 175 mg/m2 (dose level 4) had higher-grade neutropenia with cycle 2, with 1 patient experiencing febrile neutropenia. Plasma pharmacokinetic parameters of paclitaxel were unchanged between cycle 1 and 2 for dose levels 1 to 3, but at dose level 4, 45–65% increases in paclitaxel AUC were observed in 4 of the 6 patients. Mean Cmax of ONT-093 was 9 μM (range 5–15 μM) which were 3- to 5-fold higher than in single agent studies of ONT-093. Conclusions: Doses of ONT-093 achieving serum concentrations associated with biological activity were well tolerated in combination with standard doses of paclitaxel. Toxicities of the combination in this schedule were mainly attributable to paclitaxel and dose-limiting toxicity was limited to febrile neutropenia. There was an apparent pharmacokinetic interaction between paclitaxel and ONT-093, possibly related in part to the excipient, Cremophor, present in the paclitaxel formulation.
Similar content being viewed by others
References
Ling, V: Multidrug resistance: Molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 40(Suppl): S3–S8, 1997
Cordon-Carlo C, O’Brien JP, Boccia J, Casals D, Bertino J, Melamed MR: Expression of the multidrug resistance gene product (p-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277–1287, 1990
Sikic BI: Pharmacologic approaches to reversing multidrug resistance. Semin Hematol 34: S40–S47, 1997 (suppl 5)
Fracasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, Grogan TM, McGuire WP: Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: A gynecologic Oncology Group Study. J Clin Oncol 19: 2975–2982, 2001
Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, Overmoyer B, Garg V, Ette E, Harding MW, Demetri GD: Safety and efficacy of the multidrug resistance inhibitor incel (Biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res 8: 670–678, 2002
Rubin EH, de Alwis DP, Pouliquen I, Green L, Marder P, Lin Y, Musanti R, Grospe SL, Smith SL, Toppmeyer DL, Much J, Kane M, Chaudhary A, Jordan C, Burgess M, Slapak CA: A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin Cancer Res 8: 3710–3717, 2002
Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, Krane S, Moran EJ, Uyeda RT, Dixon R, Guns ES, Mayer LD: Discovery and Characterization of OC144-093, a novel inhibitor of P-glycoprotein mediated multidrug resistance. Cancer Res 60: 2964–2972, 2000
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205–216, 2000
Sonnichsen DS, Liu Q, Schuetz EG, Scheutz JD, Pappo A, Relling MV: Variability in human cytochrome P450 paclitaxel metabolism. J Pharm Exp Therap 275: 566–575, 1995.
van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K, Stoter G, Sparreboom A: Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol 47: 309–318, 2001
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chi, K.N., Chia, S.K., Dixon, R. et al. A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs 23, 311–315 (2005). https://doi.org/10.1007/s10637-005-1439-x
Issue Date:
DOI: https://doi.org/10.1007/s10637-005-1439-x